![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Regulatory authorities interpret the results of randomized controlled trials according to published principles. The European Medicines Agency (EMA) is planning a revision of the 2000 and 2003 guidance documents on clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) to achieve consistency with current knowledge in the field. This manuscript summarizes the key output from a collaborative workshop, organized by the Cardiovascular Round Table and the European Affairs Committee of the European Society of Cardiology, involving clinicians, academic researchers, trialists, European and US regulators, and pharmaceutical industry researchers. Specific questions in four key areas were selected as priorities for changes in regulatory guidance: patient selection, endpoints, methodologic issues and issues related to the research for novel agents. Patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) should be studied separately for therapies aimed at the specific pathophysiology of either condition, particularly for treatment of the acute phase, but can be studied together for other treatments, especially long-term therapy. Unstable angina patients should be excluded from acute phase ACS trials. In general, cardiovascular death and reinfarction are recommended for primary efficacy endpoints; other endpoints may be considered if specifically relevant for the therapy under study. New agents or interventions should be tested against a background of evidence-based therapy with expanded follow-up for safety assessment. In conclusion, new guidance documents for randomized controlled trials in ACS should consider changes regarding patient and endpoint selection and definitions, and trial designs. Specific requirements for the evaluation of novel pharmacological therapies need further clarification.
References
| 1. |
European Medicines Agency Committee for Proprietary Medicinal Products . Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI), http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003339.pdf (2003, accessed on 22 April 2015). Google Scholar |
| 2. |
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) . Points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent ST-segment elevation, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003363.pdf (2000, accessed on 15 September 2015). Google Scholar |
| 3. |
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) . Concept paper on the need for revision of the points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (CPMP/EWP/570/98 and CPMP/EWP/967/01), http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500175594.pdf (2014, accessed on 22 April 2015). Google Scholar |
| 4. |
Thygesen, K, Alpert, JS, Jaffe, AS. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551–2567. Google Scholar | Crossref | Medline | ISI |
| 5. |
Fox, KA, Anderson, FA, Goodman, SG. Time course of events in acute coronary syndromes: Implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5: 580–589. Google Scholar | Crossref | Medline |
| 6. |
Montalescot, G, Dallongeville, J, Van, BE. STEMI and NSTEMI: Are they so different? 1 Year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2007; 28: 1409–1417. Google Scholar | Crossref | Medline | ISI |
| 7. |
Fox, KA, Carruthers, KF, Dunbar, DR. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755–2764. Google Scholar | Crossref | Medline | ISI |
| 8. |
Steg, PG, James, SK, Atar, D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619. Google Scholar | Crossref | Medline | ISI |
| 9. |
Roffi, M, Patrono, C, Collet, JP. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315. Google Scholar | Crossref | Medline | ISI |
| 10. |
Gershlick, AH, Khan, JN, Kelly, DJ. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: The CvLPRIT trial. J Am Coll Cardiol 2015; 65: 963–972. Google Scholar | Crossref | Medline | ISI |
| 11. |
Ibanez, B, Macaya, C, Sanchez-Brunete, V. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 2013; 128: 1495–1503. Google Scholar | Crossref | Medline |
| 12. |
Layland, J, Oldroyd, KG, Curzen, N. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: The British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J 2015; 36: 100–111. Google Scholar | Crossref | Medline |
| 13. |
Yusuf, S, Zhao, F, Mehta, SR. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502. Google Scholar | Crossref | Medline | ISI |
| 14. |
Wallentin, L, Becker, RC, Budaj, A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057. Google Scholar | Crossref | Medline | ISI |
| 15. |
Wiviott, SD, Braunwald, E, McCabe, CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med 2007; 357: 2001–2015. Google Scholar | Crossref | Medline | ISI |
| 16. |
Pitt, B, Remme, W, Zannad, F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321. Google Scholar | Crossref | Medline | ISI |
| 17. |
Cannon, CP, Blazing, MA, Giugliano, RP. Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med 2015; 372: 2387–2397. Google Scholar | Crossref | Medline | ISI |
| 18. |
Mega, JL, Braunwald, E, Wiviott, SD. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19. Google Scholar | Crossref | Medline | ISI |
| 19. |
Mehta, C, Gao, P, Bhatt, DL. Optimizing trial design: Sequential, adaptive, and enrichment strategies. Circulation 2009; 119: 597–605. Google Scholar | Crossref | Medline | ISI |
| 20. |
Shroff, GR, Heubner, BM, Herzog, CA. Incidence of acute coronary syndrome in the general Medicare population, 1992 to 2009: A real-world perspective. JAMA Intern Med 2014; 174: 1689–1690. Google Scholar | Crossref | Medline |
| 21. |
Dudas, K, Bjorck, L, Jernberg, T. Differences between acute myocardial infarction and unstable angina: A longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). BMJ Open 2013; 3. Google Scholar |
| 22. |
Loh, JP, Pendyala, LK, Kitabata, H. Comparison of outcomes after percutaneous coronary intervention among different coronary subsets (stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction). Am J Cardiol 2014; 113: 1794–1801. Google Scholar | Crossref | Medline |
| 23. |
D’Souza, M, Sarkisian, L, Saaby, L. Diagnosis of unstable angina pectoris has declined markedly with the advent of more-sensitive troponin assays. Am J Med 2015; 128: 852–860. Google Scholar | Crossref | Medline |
| 24. |
Krumholz, HM, Normand, SL, Wang, Y. Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999–2011. Circulation 2014; 130: 966–975. Google Scholar | Crossref | Medline |
| 25. |
Braunwald, E, Morrow, DA. Unstable angina: Is it time for a requiem? Circulation 2013; 127: 2452–2457. Google Scholar | Crossref | Medline | ISI |
| 26. |
Bonaca, M, Scirica, B, Sabatine, M. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 2010; 55: 2118–2124. Google Scholar | Crossref | Medline | ISI |
| 27. |
Mills, NL, Lee, KK, McAllister, DA. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: Cohort study. Br Med J 2012; 344: e1533. Google Scholar | Crossref | Medline |
| 28. |
Gitt, AK, Hochadel, M, Zahn, R. Higher in-hospital mortality of NSTEMI as compared to unstable angina despite higher rate of invasive therapy in clinical practice: Results of the EHS ACS Registry [abstract]. J Am Coll Cardiol 2015; 65: A189. Google Scholar | Crossref |
| 29. |
Fox, KA, Dabbous, OH, Goldberg, RJ. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE). Br Med J 2006; 333: 1091. Google Scholar | Crossref | Medline |
| 30. |
Antman, EM, Cohen, M, Bernink, PJ. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–842. Google Scholar | Crossref | Medline | ISI |
| 31. |
National Institute for Health Care and Excellence (NICE) . Unstable angina and NSTEMI: The early management of unstable angina and non-ST-segment-elevation myocardial infarction, https://www.nice.org.uk/guidance/cg9 (2013, accessed on 5 May 2015). Google Scholar |
| 32. |
Boersma, E, Pieper, KS, Steyerberg, EW. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557–2567. Google Scholar | Crossref | Medline | ISI |
| 33. |
Bueno, H, Fernandez-Aviles, F. Use of risk scores in acute coronary syndromes. Heart 2012; 98: 162–168. Google Scholar | Crossref | Medline | ISI |
| 34. |
Pocock, S, Bueno, H, Licour, M. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study. Eur Heart J Acute Cardiovasc Care 2015; 4: 509–517. Google Scholar | SAGE Journals | ISI |
| 35. |
Fox, KA, FitzGerald, G, Puymirat, E. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014; 4: e004425. Google Scholar | Crossref | ISI |
| 36. |
Backus, BE, Six, AJ, Kelder, JH. Risk scores for patients with chest pain: Evaluation in the emergency department. Curr Cardiol Rev 2011; 7: 2–8. Google Scholar | Crossref | Medline |
| 37. |
Verheugt, FW, Clemmensen, P, Mehran, R. Antithrombotic outcome trials in acute coronary syndromes: Seeking the optimal balance between safety and efficacy. Eur Heart J 2013; 34: 1621–1629. Google Scholar | Crossref | Medline |
| 38. |
Wildi, K, Gimenez, MR, Twerenbold, R. Misdiagnosis of myocardial infarction related to limitations of the current regulatory approach to define clinical decision values for cardiac troponin. Circulation 2015; 131: 2032–2040. Google Scholar | Crossref | Medline |
| 39. |
Sandoval, Y, Smith, SW, Thordsen, SE. Supply/demand type 2 myocardial infarction: Should we be paying more attention? J Am Coll Cardiol 2014; 63: 2079–2087. Google Scholar | Crossref | Medline | ISI |
| 40. |
Mehran, R, Rao, SV, Bhatt, DL. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011; 123: 2736–2747. Google Scholar | Crossref | Medline | ISI |
| 41. |
Schulman, S, Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694. Google Scholar | Crossref | Medline | ISI |
| 42. |
Putera, M, Roark, R, Lopes, RD. Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. Am Heart J 2015; 169: 266–273. Google Scholar | Crossref | Medline |
| 43. |
Pocock, SJ, Clayton, TC, Stone, GW. Challenging issues in clinical trial design: Part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015; 66: 2886–2898. Google Scholar | Crossref | Medline | ISI |
| 44. |
van Domburg, RT, Sonnenschein, K, Nieuwlaat, R. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol 2005; 46: 15–20. Google Scholar | Crossref | Medline |
| 45. |
Ford, I, Murray, H, Packard, CJ. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477–1486. Google Scholar | Crossref | Medline | ISI |
| 46. |
Packard, CJ, Ford, I, Murray, H. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year followup of the West of Scotland Coronary Prevention study (AHA late breaking abstract). Circulation 2014; 130: 2112. Google Scholar |
| 47. |
James, S, Rao, SV, Granger, CB. Registry-based randomized clinical trials–a new clinical trial paradigm. Nat Rev Cardiol 2015; 12: 312–316. Google Scholar | Crossref | Medline | ISI |
| 48. |
Armstrong, PW, Granger, CB, Adams, PX. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. JAMA 2007; 297: 43–51. Google Scholar | Crossref | Medline | ISI |
| 49. |
Nicholls, SJ, Kastelein, JJ, Schwartz, GG. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial. JAMA 2014; 311: 252–262. Google Scholar | Crossref | Medline |
| 50. |
O’Donoghue, ML, Braunwald, E, White, HD. Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312: 1006–1015. Google Scholar | Crossref | Medline | ISI |
| 51. |
Ridker, PM, Luscher, TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782–1791. Google Scholar | Crossref | Medline | ISI |
| 52. |
Roncalli, J, Mouquet, F, Piot, C. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: Results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32: 1748–1757. Google Scholar | Crossref | Medline |
| 53. |
Sinnaeve, P, Chiche, JD, Gillijns, H. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 2002; 105: 2911–2916. Google Scholar | Crossref | Medline |
| 54. |
White, HD, Held, C, Stewart, R. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702–1711. Google Scholar | Crossref | Medline | ISI |
| 55. |
Rosenson, RS, Elliott, M, Stasiv, Y. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011; 32: 999–1005. Google Scholar | Crossref | Medline |
| 56. |
Rosenson, RS, Hislop, C, Elliott, M. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010; 56: 1079–1088. Google Scholar | Crossref | Medline |
| 57. |
Rosenson, RS, Hislop, C, McConnell, D. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373: 649–658. Google Scholar | Crossref | Medline |
| 58. |
Granger, CB, Mahaffey, KW, Weaver, WD. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184–1190. Google Scholar | Crossref | Medline |
